Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Catalyst Pharmaceuticals, Inc. - Common Stock (NQ:CPRX)

23.76 -0.17 (-0.71%)
Streaming Delayed Price Updated: 3:01 PM EST, Feb 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Catalyst Pharmaceuticals, Inc. - Common Stock

News headline image
Amylyx Pharmaceuticals Stock Sees Relative Strength Rating Rise To 98 ↗
Amylyx Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating improve to 98, up from 83 the day before. 
Via Investor's Business Daily
News headline image
Agios Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating ↗
Agios Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an increase from 65 to 93. 
Via Investor's Business Daily
News headline image
Legend Biotech Stock Joins Elite Club Of Stocks With RS Ratings Over 90 ↗
On Thursday, Legend Biotech stock had its Relative Strength (RS) Rating upgraded to 91, up from 87 a day earlier. 
Via Investor's Business Daily
News headline image
Intercept Pharmaceutical Stock Shows Market Leadership; Earns 92 RS Rating ↗
On Tuesday, Intercept Pharmaceutical stock had its Relative Strength Rating upgraded to 92, up from 89 a day earlier. 
Via Investor's Business Daily
News headline image
15 Biotech Stocks That Hit Year Highs Over The Last Week, Including Sarepta, Axsome ↗
Not all shares are slowing down alongside the industry group. 
Via Investor's Business Daily
News headline image
Piper Sandler Increases Catalyst Pharma's Price Target Slightly After Q4 Earnings ↗
 
Via Benzinga
News headline image
Relay Therapeutics Stock Shows Market Leadership With Jump To 94 RS Rating ↗
Relay Therapeutics stock saw a positive improvement to its Relative Strength (RS) Rating on Thursday, with an upgrade from 84 to 94. 
Via Investor's Business Daily
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 24, 2022 ↗
  
Via Benzinga
News headline image
Kymera Therapeutics Stock Scores Rising Relative Price Strength ↗
Kymera Therapeutics stock hit a key performance benchmark, with its Relative Strength Rating upgradedjulie mak to 94. 
Via Investor's Business Daily
News headline image
Rocket Pharmaceuticals Stock Scores Rising Relative Strength Upgrade ↗
On Thursday, Rocket Pharmaceuticals stock received an upgrade to its Relative Strength (RS) Rating, from 88 to 94. 
Via Investor's Business Daily
News headline image
11 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
  Gainers   
Via Benzinga
News headline image
Catalyst Pharmaceuticals: Q2 Earnings Insights ↗
  Catalyst Pharmaceuticals (NASDAQ:CPRX) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Why Catalyst Pharmaceuticals Shares Are Moving Today ↗
Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) shares are trading lower by 1.47% at $10.71. Traders and investors are watching for the company’s second-quarter earnings report, confirmed for Tuesday’s... 
Via Benzinga
News headline image
Kura Oncology Stock Joins Rank Of Stocks With RS Ratings Over 90 ↗
On Monday, Kura Oncology stock had its Relative Strength (RS) Rating upgraded to 91, up from 85 a day earlier. 
Via Investor's Business Daily
News headline image
A Preview Of Catalyst Pharmaceuticals' Earnings ↗
  Catalyst Pharmaceuticals (NASDAQ:CPRX) is set to give its latest quarterly earnings report on Tuesday, 2022-08-09. Here's what investors need to know before the announcement. 
Via Benzinga
News headline image
Catalyst Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 9, 2022
The Company Will Host a Conference Call and Webcast on August 10, 2022, at 8:30 AM ET 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
The Daily Biotech Pulse: GSK To Supply 50M Flu Vaccine Doses To US, FDA Lifts Hold On Greenwich's Cancer Immunotherapy Trial, Connect Biopharma Sees CBP-201 Topline Data Sooner ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
6 Best-Performing Robinhood Stocks Of 2022 ↗
The SPDR S&P 500 ETF Trust (NYSE: SPY) is off to a brutal start to 2022, down 12.1% year-to-date. Robinhood Markets Inc (NASDAQ: HOOD) has been one of the worst performers of all so far this year,... 
Via Benzinga
News headline image
7 Smart Stocks to Buy Now Under $10 ↗
There are always good stocks to buy somewhere. What you should be focused on is finding the smart stocks that add value to your portfolio. 
Via InvestorPlace
News headline image
This Coal Company's 1-Year Return Handily Beats Moderna, Catalyst Pharmaceuticals, Globalstar And Dogecoin ↗
Alpha Metallurgical Resources Inc (NYSE:AMR) is known as a le... 
Via Benzinga
News headline image
Catalyst Pharmaceuticals's Return On Capital Employed Insights ↗
According to Benzinga Pro data Catalyst Pharmaceuticals (NASDAQ:CPRX) posted a 9.88% decrease in earnings from Q3. Sales, however, increased by 6.55% over the previous quarter to... 
Via Benzinga
News headline image
Recap: Catalyst Pharmaceuticals Q4 Earnings ↗
Catalyst Pharmaceuticals (NASDAQ:CPRX) reported its Q4 earnings results on Wednesday, March 16, 2022 at 04:00 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
Earnings Scheduled For March 16, 2022 ↗
Companies Reporting Before The Bell • Ideanomics (NASDAQ:IDEX) is likely to report quarterly loss at $0.05 per share on revenue of $33.20 million. • Tarena... 
Via Benzinga
News headline image
Earnings Preview For Catalyst Pharmaceuticals ↗
Catalyst Pharmaceuticals (NASDAQ:CPRX) is set to give its latest quarterly earnings report on Wednesday, 2022-03-16. Here's what investors need to know before the announcement.... 
Via Benzinga
News headline image
Catalyst Pharma Expects FY22 Revenue Beat Consensus On Continued Recovery In Macroeconomic, Healthcare Activity ↗
Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) anticipates  
Via Benzinga
News headline image
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings ↗
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments... 
Via Benzinga
News headline image
7 of the Top-Rated Pharmaceutical Stocks for Q1 ↗
As the market begins to shift from high-growth, tech-fueled start-ups, one good long-term growth option is quality pharmaceutical stocks. 
Via InvestorPlace
News headline image
47 Biggest Movers From Yesterday ↗
Gainers Nuvectis Pharma, Inc. (NASDAQ: NVCT) shares surged 144.6% to close at $7.95 on Monday. The company, on Friday, priced its IPO at $5 per share. Anghami Inc. (NASDAQ: ANGH... 
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.